You are here

Home » Content

Hemodiyaliz Hastalarında Sinakalsetin Serum Kalsiyum, Fosfor, ve Paratiroid Hormon Düzeylerine Etkisi

The effect of Cinacalcet on Serum Calcium, Phosphorus and Parathyroid Hormone in Hemodialysis Patients

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2012
DOI: 
http://dx.doi.org/10.5505/abantmedj.2012.03522

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Background: The purpose of this study is to examine the effect of cinacalcet on serum calcium, phosphorus, and parathyroid hormone in hemodialysis patients. Method: This study was performed in 15 hemodialysis patients. The medical records of patients taking cinacalcet for three months were examined. Biochemical tests and blood pressure were recorded. The statistical analysis was performed using SPSS v 15.0. P< 0.05 was considered statistically significant. Results: There were statistically significant decreases in calcium, calcium x phosphorus product and parathyroid hormone levels (P=0.001, P=0.04 and P=0.009 respectively). Phosphorus level was reduced but not significantly. Nausea was observed in three patients, nausea and vomiting in three patients, as well as hypocalcaemia. Conclusion: Cinacalcet significantly reduced serum calcium, calcium x phosphorus product, and parathyroid hormone levels in hemodialysis patients. Nausea, vomiting, and hypocalcaemia often develop during the therapy. However, further studies are needed in larger patients.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Bu çalışmanın amacı hemodiyaliz hastalarında sinakalset kullanımının serum kalsiyum, fosfor ve paratiroid hormon üzerindeki etkisini incelemektir. Yöntem: Çalışma, 15 (9 E, 6 K) hemodiyaliz hastasında yapıldı. 3 ay süre ile sinakalset kullanan hastaların retrospektif olarak dosyaları incelendi. Biyokimya tetkikleri ve kan basıncı kayıtları kaydedildi. İstatistiksel analizler SPSS v 15 ile gerçekleştirildi. Bulgular: Serum kalsiyum, kalsiyum x fosfor ürünü ve paratiroid hormon düzeylerinde istatistiksel olarak anlamlı azalmalar saptandı (sırasıyla P=0.001, P=0.04 ve P=0.009). Fosfor düzeyi azalmakla birlikte farklılık istatistiksel olarak anlamlı bulunmadı. Üç hastada bulantı, üç hastada ise bulantı ve kusma gözlendi. Ayrıca üç hastada kalsiyum seviyesi 8 mg/dl’nin altına düştü. Sonuç: Sinakalset hemodiyaliz hastalarında serum kalsiyum, kalsiyum x fosfor ürünü ve paratiroid hormon düzeylerini anlamlı olarak azaltmaktadır. Tedavi sırasında bulantı, kusma ve hipokalsemi sık görülmektedir. Ancak, daha fazla hasta üzerinde yapılacak çalışmalara ihtiyaç vardır.
FULL TEXT (PDF): 
PDF icon arastirmax-hemodiyaliz-hastalarinda-sinakalsetin-serum-kalsiyum-fosfor-paratiroid-hormon-duzeylerine-etkisi.pdf
  • 2
55-60
  • Turkish

REFERENCES

References: 

1. Moe SM, Drüeke T, Lameire N, Eknoyan G. Chronic
kidney disease-mineral-bone disorder: a new paradigm.
Adv Chronic Kidney Dis 2007; 14: 3-12.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG,
Chertow GM. Mineral metabolism, mortality, and morbidity
in maintenance hemodialysis. J Am Soc Nephrol
2004; 15: 2208–2218.
3. Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL,
Neufeld TK, Hebbar S, Muther RS. Medication prescribing
patterns in ambulatory haemodialysis patients:
comparisons of USRDS to a large not-for-profit dialysis
provider. Nephrol Dial Transplant 2004; 19: 1842–1848.
4. Komaba H, Tanaka M, Fukagawa M. Treatment of
Chronic Kidney Disease-Mineral and Bone Disorder
(CKD-MBD). Inter Med 2008; 47: 989-994.
5. Nagano N. Pharmacological and clinical properties of
calcimimetics: calcium receptor activators that afford an
innovative approach to controlling hyperparathyroidism.
Pharmacol Ther 2006; 109: 339–365.
6. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram
MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK,
Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel
P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson
KA, Drüeke TB, Goodman WG. Cinacalcet for secondary
yperparathyroidism in patients receiving hemodialysis.
N Engl J Med 2004; 350: 1516–1525.
7. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port
FK. Association of elevated serum PO(4), CaxPO(4)
product, and parathyroid hormone with cardiac mortality risk in chronic haemodialysis patients. J Am Soc
Nephrol 2001;12: 2131–2138.
8. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW,
Bos WJ, Krediet RT. The K/DOQI guideline for bone metabolism
and disease in CKD: association with mortality
in dialysis patients. Am J Kidney Dis 2005; 46: 925–932.
9. London GM, Marty C, Marchais SJ, Guerin AP, Metivier
F, de Vernejoul MC. Arterial calcifications and bone histomorphometry
in end-stage renal disease. J Am Soc
Nephrol 2004; 15: 1943–1951.
10. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E,
Luft FC. Electron beam computed tomography in the
evaluation of cardiac calcification in chronic dialysis patients.
Am J Kidney Dis 1996; 27: 394–401.
11. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson
JE. Cardiac valve calcification as an important
predictor for all-cause mortality and cardiovascular
mortality in long-term peritoneal dialysis patients: a
prospective study. J Am Soc Nephrol 2003; 14: 159–168.
12. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman
SB, Fineberg N, Kopecky K. Medial artery calcification
in ESRD patients is associated with deposition of
bone matrix proteins. Kidney Int 2002; 61: 638–647.
13. National Kidney Foundation: K/DOQI Clinical Practice
Guidelines for Bone Metabolism and Disease in Chronic
Kidney Disease. Am J Kidney Dis 2003 (suppl 3); 42: S1-
S202.
14. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B,
Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff
RM, Salusky IB. Coronary-artery calcification in youngadults with end-stage renal disease who are undergoing
dialysis. N Engl J Med 2000; 342: 1478-1483.
15. Goodman WG. Recent developments in the management
of secondary hyperparathyroidism. Kidney Int
2001; 59: 1187–1201.
16. Messa P, Macario F, Yaqoob M, et al. Assessing a New
Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for
Secondary Hyperparathyroidism. Clin J Am Soc Nephrol
2008; 3: 36–45.
17. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV,
Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD,
Albizem MB, Coburn JW. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism
in hemodialysis and peritoneal dialysis:
A randomized double-blind, multicenter study. J Am
Soc Nephrol 2005; 16: 800–807.
18. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M,
Rappaport K, Ling X, Goodman WG, Turner S, Charytan
C. Cinacalcet HCl and concurrent low-dose vitamin D
improves treatment of secondary hyperparathyroidism
in dialysis patients compared with vitamin D alone: the
ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3:
1718-1725.

Thank you for copying data from http://www.arastirmax.com